https://www.selleckchem.com/products/4-hydroxytamoxifen-4-ht-afimoxifene.html 798). Moreover, there was no significant difference in either the overall survival benefit (hazard ratio [HR] = 0.84, 95% confidence interval [CI] 0.49-1.45, P = 0.532) or disease-free survival rate (HR = 0.95, 95% CI 0.52-1.75, P = 0.864). CONCLUSIONS The evidence obtained does not support PCI therapy in the management of surgically resected SCLC with no lymph node involvement. KEY POINTS Prophylactic cranial irradiation (PCI) remains controversial for resected small-cell lung cancer (SCLC) without lymph node involvement. In this study, the results indicated that PCI does not reduce the risk of cerebral recurrence of resected p-T1-2N0M0 SCLC. This is the largest sample size study focused on PCI in resected p-T1-2N0M0 SCLC. Future revised versions of the guidelines should address this issue. © 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.A structurally identifiable micro-rate constant mechanistic model was used to describe the interaction between pitavastatin and eltrombopag, with improved goodness-of-fit values through co-measurement of pitavastatin and eltrombopag. Transporter association and dissociation rate constants and passive rates out of the cell were similar between pitavastatin and eltrombopag. Translocation into the cell through transporter mediated uptake was six times greater for pitavastatin, leading to pronounced inhibition of pitavastatin uptake by eltrombopag. The passive rate into the cell was 91 times smaller for pitavastatin compared to eltrombopag. A semi-mechanistic PBPK model was developed to evaluate the potential for clinical drug-drug interactions. The PBPK model predicted a two fold increase in the pitavastatin Cmax and AUC in the presence of eltrombopag in simulated healthy volunteers. The use of structural identifiability supporting experimental design, combined with robust micro-rate constant pa